Join Us For a Live Webinar
DRUG-DRUG INTERACTION TESTING (DDI)
KEY FINDINGS FROM FIRST 100,000 SAMPLES
Since its introduction to the market in early 2016, Drug-Drug Interaction (DDI) Testing has changed the way healthcare providers care for their patients by objectively identifying substances – medications, supplements, and foods – that the patient recently ingested and are known causes of DDIs that put patients at increased risk for adverse drug events. Aegis’s DDI Testing offers healthcare providers clinically-actionable information that empowers them to combat adverse drug events seen in their patients.
Join us on Thursday, September 14, 2017 to learn what analysis of Aegis’s first 100,000 DDI samples has revealed about a patient’s increased risk of experiencing a drug-drug interaction with the number of medications consumed.
JOIN OUR WEBINAR | Thursday, September 14, 2017
Presented by: Amber Watson, Pharm. D., Aegis Sciences Corporation